Zaloguj się

Gotowe bibliografie tematyczne / Pregnancy disease / Artykuły w czasopismach

Artykuły w czasopismach na temat „Pregnancy disease”

Kliknij ten link, aby zobaczyć inne rodzaje publikacji na ten temat: Pregnancy disease.

Autor: Grafiati

Data publikacji: 14 marca 2024

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Pregnancy disease”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.

1

Batyrovna, Tilyakhodjaeva Gulbakhor. "PECULIARITIES OF VARICOSE VEIN DISEASE IN PREGNANCY". International Journal of Medical Sciences And Clinical Research 02, nr 04 (1.04.2022): 1–6. http://dx.doi.org/10.37547/ijmscr/volume02issue04-01.

Pełny tekst źródła

Streszczenie:

The article under discussion depicts peculiarities of varicose vein disease in pregnancy. Venous disease in women often complicates pregnancy, childbirth and the postpartum period. Venous insufficiency complicates pregnancy, delivery and postpartum period and leads to increased maternal morbidity and mortality. The author of the article considers that correction of placental dysfunction, especially in the early stages, can significantly improve perinatal outcomes.

Style APA, Harvard, Vancouver, ISO itp.

2

Dissemond, Joachim, Philipp Al Ghazal, Katharina Herberger, Jörg Schaller i Anke Strölin. "Significant Exacerbation of Darier's Disease and Pregnancy". Dermatology and Dermatitis 3, nr 1 (1.10.2018): 01–04. http://dx.doi.org/10.31579/2578-8949/044.

Pełny tekst źródła

Streszczenie:

Darier's disease, also known as keratosis follicularis or Darier-White disease, is an autosomal dominant inherited condition. The disease usually has its onset in the teenage years, meaning it co-exists with the years of fertility in women. The potential dermatological and obstetric implications of Darrier's Disease, especially when it involves the groin and vulva, have not been well reported. We report a case of Darier's Disease associated with multiple antibiotic resistant folliculitis involving skin of the breasts, groin, vulva and perineum that precluded safe vaginal delivery.

Style APA, Harvard, Vancouver, ISO itp.

3

Modiya, Dr Rohan A., Dr Shirish B. Raval i Dr Seema S. Khetani. "Outcome in Rheumatic Heart Disease in Pregnancy". International Journal of Scientific Research 1, nr 7 (1.06.2012): 159–60. http://dx.doi.org/10.15373/22778179/dec2012/58.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

4

Rakhimovna, Khudoyarova Dildora, i Yusupov Orzimurod Shomurodovich. "VARICOSE DISEASE AND PRECNANCY". International Journal of Medical Sciences And Clinical Research 03, nr 04 (1.04.2023): 50–54. http://dx.doi.org/10.37547/ijmscr/volume03issue04-07.

Pełny tekst źródła

Streszczenie:

The article presents observational data of patients with varicose veins and analyzes the course of pregnancy. The patients were divided into three groups depending on the type of varicose veins, the control group consisted of healthy pregnant women who developed varicose veins during this pregnancy. The work was carried out on the basis of the Department of Obstetrics and Gynecology No. 1 of the Samarkand State Medical University. The study revealed exacerbation of the phenomena of varicose veins in the second - third trimester of pregnancy, as well as complications of pregnancy compared with the control group.

Style APA, Harvard, Vancouver, ISO itp.

5

Golovach, I. Yu, i Ye D. Yehudina. "Perygravid management of rheumatic disease". HEALTH OF WOMAN, nr 2(148) (30.03.2020): 42–51. http://dx.doi.org/10.15574/hw.2020.148.42.

Pełny tekst źródła

Streszczenie:

Management of inflammatory rheumatic diseases in preconception period, pregnancy and breastfeeding has undergone significant changes over the past few years. Modern therapy, including biological and targeted synthetic disease modifying drugs, has significantly improved the control of rheumatic diseases, which has led to an increase in the patients’ number planning a pregnancy with serious diseases. When consulting such patients, it is necessary to discuss the possible time of conception (regarding the activity of the disease), the effect of the disease on pregnancy and pregnancy on the disease, as well as the potential need to change the regimen of medications during pregnancy and breastfeeding. This review summarizes information on the effects of pregnancy on various rheumatic diseases and vice versa, changes in therapy and monitoring of patients with rheumatic diseases before, during and after pregnancy. Women with inflammatory rheumatic diseases need advice on drug therapy before planning pregnancy, during pregnancy, and breastfeeding. Safe disease-modifying drugs that can be taken during pregnancy are hydroxychloroquine, sulfosalazine, azathioprine, and cyclosporine. Glucocorticoids and non-steroidal anti-inflammatory drugs can also be taken up to 32 weeks of gestation. Most inhibitors of tumor necrosis factor (anti-TNF) are also safe during pregnancy. During pregnancy, a clear monitoring of the activity of the disease is necessary, control of the level of autoantibodies, especially anti-SSA / Ro and anti-SSB / La and antiphospholipid antibodies, an assessment of the degree of organ dysfunction, especially kidney damage. Presented are modern approaches to optimizing the management of inflammatory rheumatic disease during pregnancy. For patients with inflammatory rheumatic diseases, a successful pregnancy outcome is optimized by creating an individual plan to suppress disease activity using a targeted approach. Key words: pregnancy, rheumatic diseases, treatment, lactation, management tactics, drugs.

Style APA, Harvard, Vancouver, ISO itp.

6

Davies, Gregory A. L., i William N. P. Herbert. "HEART DISEASE IN PREGNANCY 2: Congenital Heart Disease in Pregnancy". Journal of Obstetrics and Gynaecology Canada 29, nr 5 (maj 2007): 409–14. http://dx.doi.org/10.1016/s1701-2163(16)35492-5.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

7

Vyas, Rupa, Priya Gupta, Sapana Shah i Komal Rangoliya. "Cardiovascular disease in pregnancy". International Journal of Reproduction, Contraception, Obstetrics and Gynecology 8, nr 9 (26.08.2019): 3789. http://dx.doi.org/10.18203/2320-1770.ijrcog20193821.

Pełny tekst źródła

Streszczenie:

Background: Maternal cardiac disease is a major cause of non-obstetric maternal morbidity and mortality. The care of pregnant women with cardiac disease requires a multidisciplinary approach, involving obstetricians, cardiologists and anesthesiologist.Methods: A prospective analytical study of maternal heart disease and its fetomaternal outcome is carried out in the department of obstetrics and gynecology at tertiary hospital and teaching institute. The study was carried out on 50 cases belonging to age group 18-50 years with various cardiac diseases during their pregnancy and peripartum period.Results: In this study, 78% of the cases were registered with our hospital. The present study shows about 32% of the women having cardiac disease were in the age group of 20-25 years. 34% belonged to NYHA class II and had a relatively uneventful peripartum period. Among all forms of heart disease, RHD was common constituting 26% of cases. Most common condition associated with cardiac disease in pregnancy was preeclampsia (36%) in our study, with anemia being other one (10%). The common complications were congestive cardiac failure (12%) and pulmonary edema (8%). Combination of diuretics and beta blockers was used most commonly (22%). 56% of women delivered with caesarean section. 42 patients delivered after age of viability with 29 (69%) term deliveries and 13 (30%) preterm deliveries with 8 requiring NICU care.Conclusions: Valvular heart disease of rheumatic origin is the most common cardiac disease associated with pregnancy.The availability of adequate systems of early diagnosis of cardiac lesion, reference to tertiary care center & close monitoring of patient and delivery with multidisciplinary approach include specialized cardiologic care, high risk obstetric support and neonatology expertise that can minimize the serious consequences and helps to improve fetomaternal outcome. Pre-conceptional counseling and surgical correction of certain conditions improves maternal as well as fetal outcome. Awareness needs to be created about heart diseases during pregnancy and the importance of regular antenatal check-ups.

Style APA, Harvard, Vancouver, ISO itp.

8

Erez, Y., S. B. Kocaer, G. Can, M. Birlik, F. Onen i İ. Sari. "AB0769 Treatment outcomes of patients with biological therapy during pregnancy and effect of pregnancy planning on treatment preferance of rheumatologists". Annals of the Rheumatic Diseases 81, Suppl 1 (23.05.2022): 1511.1–1511. http://dx.doi.org/10.1136/annrheumdis-2022-eular.3115.

Pełny tekst źródła

Streszczenie:

BackgroundRheumatic diseases occur mostly in adults at reproductive age. In addition to the impact of disease course on fetal and maternal health, safety concerns regarding the effects of biological drugs on the course of pregnancy have come to the fore with the introduction and widespread use of them. Unlike other biological treatments, all tumor necrosis factor (TNF) antagonists can be used during pregnancy.ObjectivesTo investigate clinical features, treatment characteristics and pregnancy outcomes of patients with biological treatment and evaluate impact of planning pregnancy on treatment preferance.MethodsThe study was planned between January 2015 and December 2021. Patients who received biological treatment at conception were determined retrospectively. Demographycal data, clinical features, treatment characteristics and pregnancy outcomes were recorded.Results15 patients (mean age 37.2±4) were included. Mean age at diagnosis was 25.6±5.4 and age at gestational was 33±3.9. Mean follow-up duration was 96±55 months. Median period of biological therapy was found 37 (1-156) months. Six (40%) patients were diagnosed with Axial Spondyloarthritis, 6 (40%) Psoriatic Arthritis, 1 (6.6%) Rheumatoid arthritis. While 12 (80%) patients had planned (wanted) pregnancies, 10 (66%) patients were evaluated as eligible for pregnancy in terms of rheumatological disease by rheumatologists. 13 (86.6%) patients were in remission/partial remission before pregnancy. 5 (33.3%) patients were using steroid and disease modifying anti-rheumatic drugs (DMARDs) were stopped before conception. 10 (66.6%) patients were receiving certolizumab, 4 (26.7%) patients were receiving adalimumab. It was found that the treatment of the patient who received rituximab was interrupted due to the pregnancy planning. While certolizumab treatment continued in 6 (60%) patients during pregnancy, the treatment of patients receiving adalimumab was discontinued within first trimester. Activation of disease was occurred in 2 patients whose therapy interrupted. Biological treatment was restarted during pregnancy in 3 of 9 patients whose biological treatment was discontinued. No perinatal complication was developed except premature rupture of membranes in one patient. It was observed that all infants were healthy at birth, but baby of the mother who received certolizumab was diagnosed mental retardation in early childhood.ConclusionIn this study, it was established that the majority of patients using TNF antagonist during pregnancy;1-Having wanted/planned pregnancy,2-Being in remission or low disease activity before pregnancy,3-Not experiencing disease activation during pregnancy.In this study, it was concluded that having a pregnancy plan may be an important factor for rheumatologists to decide type of TNF antagonist, and physicians tend to prefer certolizumab in patients with pregnancy plan.Table 1.Baseline clinical and treatment characteristicsAge, years37.2±4Age, at diagnosis25.6±5.4Age, at gestation33±3.9Follow-up duration, months96±55Biologic treatment duration, months37 (1-156)Rheumatologic diseasen (%) -Spondyloarthritis6 (40) -Psoriatic arthritis6 (40) -Rheumatoid arthritis1 (6.6) -Behcet disease1 (6.6) -Systemic lupus eritematosus1 (6.6)Biologic treatmentn (%) -Certolizumab*10 (66.6) -Adalimumab*4 (26.7)Discontinuation of treatment9 (60)Restart3 (33.3)Disease activityRemission/partial remission*13 (86.6)Activation during pregnancy3 (20)*At conceptionDisclosure of InterestsNone declared

Style APA, Harvard, Vancouver, ISO itp.

9

N.I., Zakirova. "MANAGEMENT OF PREGNANT WOMEN WITH THYROID DISEASE". Frontline Medical Sciences and Pharmaceutical Journal 02, nr 03 (1.03.2022): 122–27. http://dx.doi.org/10.37547/medical-fmspj-02-03-13.

Pełny tekst źródła

Streszczenie:

The course of pregnancy, thyroid status, hormonal levels were studied in 96 women with autoimmune thyroiditis (AIT). It was found that pregnant women have a number of complications (54.8%) from the mother and the fetus, AIT has an unfavorable effect on the course of pregnancy, there is a high risk of miscarriage and termination of pregnancy, there is a decrease in the level of thyroid hormones and an increase in the level of TSH in comparison with similar indicators of healthy pregnant women. For the prevention of complications of gestation and prematurity of pregnancy in women with AIT, a planned determination of TSH blood from early gestation is recommended.

Style APA, Harvard, Vancouver, ISO itp.

10

Gross man, R. F., i Sami Micheal. "Management Thyroid Disease in Pregnancy: Preconception, and the Postpartum Complications". Endocrinology and Disorders 1, nr 3 (5.12.2017): 01–04. http://dx.doi.org/10.31579/2640-1045/012.

Pełny tekst źródła

Streszczenie:

Pregnancy has a profound impact on the thyroid gland and thyroid function since the thyroid may encounter changes to hormones and size during pregnancy. The diagnosis and treatment of thyroid disease during pregnancy and the postpartum is complex but knowledge regarding the interaction between the thyroids and pregnancy/the postpartum period is advancing at a rapid pace. For women known to have hypothyroidism, an increase in thyroxine dose by 20–40% when pregnancy is confirmed usually ensures they remain euthyroid. Treatment of subclinical hypothyroidism is recommended if the woman has antithyroid antibodies. Treatment of hyperthyroidism, unless it is related to human chorionic gonadotrophin, involves propylthiouracil in the first trimester. Carbimazole may be used in the second trimester. Thyroid function tests are checked every month and every two weeks following a change in dose. Women with a current or a past history of Graves’ disease who have thyrotropin receptor antibodies require early specialist referral as there is a 1–5% risk of fetal hyperthyroidism. Women with thyroid disorders in pregnancy should be followed up by their GP in the postpartum period. Postpartum thyroiditis may present months after delivery.

Style APA, Harvard, Vancouver, ISO itp.

11

Leslein, Nicholas. "Pregnancy and Lyme disease". Proceedings in Obstetrics and Gynecology 1, nr 1 (2.04.2010): 1–4. http://dx.doi.org/10.17077/2154-4751.1011.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

12

Elizabeth, N. Pearce, i M. Leung Angela. "Thyroid Disease in Pregnancy". US Endocrinology 04, nr 01 (2008): 100. http://dx.doi.org/10.17925/use.2008.04.01.100.

Pełny tekst źródła

Streszczenie:

The spectrum of thyroid disease in pregnancy has implications for both the mother and the developing fetus. Here we review the interpretation of thyroid function test values, thyrotoxicosis, hypothyroidism, iodine requirements, autoimmune thyroid disease, and thyroid screening recommendations as they pertain to pregnant women. It should be noted that the management of thyroid dysfunction in pregnancy should be closely co-ordinated with obstetricians and other providers.

Style APA, Harvard, Vancouver, ISO itp.

13

Hill, Alexandria J., i Luis D. Pacheco. "Cardiovascular Disease in Pregnancy". NeoReviews 13, nr 11 (listopad 2012): e651-e660. http://dx.doi.org/10.1542/neo.13-11-e651.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

14

Atapattu, Piyusha. "Thyroid disease in pregnancy". Ceylon Medical Journal 52, nr 1 (9.09.2009): 24. http://dx.doi.org/10.4038/cmj.v52i1.1044.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

15

Blom, Kimberly, Ayodele Odutayo, Kate Bramham i Michelle A. Hladunewich. "Pregnancy and Glomerular Disease". Clinical Journal of the American Society of Nephrology 12, nr 11 (18.05.2017): 1862–72. http://dx.doi.org/10.2215/cjn.00130117.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

16

Gopal, Raju A., Shrikrishna V. Acharya, Tushar R. Bandgar, Padma S. Menon i Nalini S. Shah. "Cushing disease with pregnancy". Gynecological Endocrinology 28, nr 7 (2.05.2012): 533–35. http://dx.doi.org/10.3109/09513590.2011.632789.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

17

Villablanca, Amparo C. "Heart disease during pregnancy". Postgraduate Medicine 104, nr 4 (październik 1998): 183–92. http://dx.doi.org/10.3810/pgm.1998.10.460.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

18

Villablanca, Amparo C. "Heart disease during pregnancy". Postgraduate Medicine 104, nr 5 (listopad 1998): 149–55. http://dx.doi.org/10.3810/pgm.1998.11.407.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

19

Elliott, C., K. Sliwa i R. Burton. "Pregnancy and cardiac disease". South African Medical Journal 104, nr 9 (3.08.2014): 641. http://dx.doi.org/10.7196/samj.8762.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

20

Arafeh, J., i Y. Y. El-Sayed. "Cardiac Disease in Pregnancy". NeoReviews 5, nr 6 (1.06.2004): e232-e239. http://dx.doi.org/10.1542/neo.5-6-e232.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

21

Nanda, Surabhi, Catherine Nelson-Piercy i Lucy Mackillop. "Cardiac disease in pregnancy". Clinical Medicine 12, nr 6 (grudzień 2012): 553–60. http://dx.doi.org/10.7861/clinmedicine.12-6-553.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

22

Frise, Charlotte J., i Catherine Williamson. "Endocrine disease in pregnancy". Clinical Medicine 13, nr 2 (kwiecień 2013): 176–81. http://dx.doi.org/10.7861/clinmedicine.13-2-176.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

23

Baldeweg, Stephanie E. "Endocrine disease in pregnancy". Clinical Medicine 13, nr 4 (sierpień 2013): 417.1–417. http://dx.doi.org/10.7861/clinmedicine.13-4-417.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

24

Avramenko, T. V. "Thyroid Disease and Pregnancy". HEALTH OF WOMAN, nr 4(110) (30.05.2016): 10–13. http://dx.doi.org/10.15574/hw.2016.110.10.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

25

Melo, João D., Bráulio Gomes, José P. Leite i Mercedes Agúndez. "McArdle Disease and Pregnancy". Galicia Clínica 76, nr 4 (2015): 169. http://dx.doi.org/10.22546/34/823.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

26

Stagnaro-Green, Alex. "PREGNANCY AND THYROID DISEASE". Immunology and Allergy Clinics of North America 14, nr 4 (listopad 1994): 865–78. http://dx.doi.org/10.1016/s0889-8561(22)00349-6.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

27

Tejeswini, Dr P. Lakshmi, i Dr Nandhini Elumalai. "Addison’s Disease in Pregnancy". IOSR Journal of Dental and Medical Sciences 16, nr 03 (marzec 2017): 22–23. http://dx.doi.org/10.9790/0853-1603102223.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

28

Rachkonda, Lakshmi, Suresh Rawte i Swati Shiradkar. "Cardiovascular Disease and Pregnancy". Indian Journal of Maternal-Fetal and Neonatal Medicine 3, nr 1 (2016): 27–35. http://dx.doi.org/10.21088/ijmfnm.2347.999x.3116.6.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

29

Quinlivan, Julie A., i Louise C. O'Halloran. "Dariers disease and pregnancy". Dermatology Aspects 1, nr 1 (2013): 1. http://dx.doi.org/10.7243/2053-5309-1-1.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

30

Quinlivan, Julie A., i Louise C. O'Halloran. "Dariers disease and pregnancy". Dermatology Aspects 1, nr 1 (2013): 2. http://dx.doi.org/10.7243/2053-5309-1-2.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

31

Lee, Noel M., i Carla W. Brady. "Liver disease in pregnancy". World Journal of Gastroenterology 15, nr 8 (2009): 897. http://dx.doi.org/10.3748/wjg.15.897.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

32

Clark, Steven L. "Cardiac Disease in Pregnancy". Obstetrics and Gynecology Clinics of North America 18, nr 2 (czerwiec 1991): 237–56. http://dx.doi.org/10.1016/s0889-8545(21)00270-9.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

33

Mcilvaine, Susan, Loryn Feinberg i Melissa Spiel. "Cardiovascular Disease in Pregnancy". NeoReviews 22, nr 11 (1.11.2021): e747-e759. http://dx.doi.org/10.1542/neo.22-11-e747.

Pełny tekst źródła

Streszczenie:

Cardiovascular disease remains a major contributor to rising maternal morbidity and mortality. Both the pregnant woman and fetus are exposed to many potential complications as a result of the physiologic changes of pregnancy. These changes can exacerbate existing cardiac disease, as well as lead to the development of de novo issues during gestation, delivery, and the postnatal period. For women with preexisting cardiac disease, including congenital malformations, valvular disease, coronary artery disease, and aortopathies, it is crucial that they receive multidisciplinary evaluation, counseling, and optimization before conception, as well as close monitoring and medication management during pregnancy. Close monitoring is also essential for patients who develop cardiovascular complications such as preeclampsia, cardiomyopathy, congestive heart failure, coronary events, and arrhythmias during pregnancy. In addition, concerning disparities in maternal morbidity and mortality exist across many dimensions, in part because of the lack of uniformity of care in different treatment settings. Establishment of multidisciplinary cardio-obstetric teams including representatives from cardiology, anesthesia, obstetrics, maternal-fetal medicine, and specialized nursing has proven instrumental to delivering evidence-based and equitable care to high-risk patients. Multidisciplinary teams should work to guide these patients through the preconception, antepartum, delivery, and postpartum phases to ensure appropriate care for weeks to years after pregnancy.

Style APA, Harvard, Vancouver, ISO itp.

34

Araújo, Amanda Carolina Mendes, Maeli da Silva Antunes, Geice Gabrieli Ribeiro Rocha, Márcia Ramos de Paulo i Gleison Faria. "Pregnancy-specific hypertensive disease". International Journal of Advanced Engineering Research and Science 8, nr 10 (2021): 174–78. http://dx.doi.org/10.22161/ijaers.810.19.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

35

Yousaf, Farah. "PREGNANCY WITH CARDIAC DISEASE;". Professional Medical Journal 24, nr 01 (18.01.2017): 106–9. http://dx.doi.org/10.29309/tpmj/2017.24.01.490.

Pełny tekst źródła

Streszczenie:

Objective: Objective of study was to find out prevalence and fetal and maternaloutcome in pregnancy with cardiac disease. Study design: A retrospective descriptive study.Setting: Services Hospital Department of Obs and Gynae unit-2. Period: 1st January to 31stDecember 2015. Methodology: All cardiac patients who delivered after 28 week gestation wereincluded in the study. Case-notes of cardiac patients were reviewed, patients age, parity andgestational age was recorded. Maternal and fetal outcome was noted in relation with NYHAclassification, data was analyzed. Results: In our study prevalence of cardiac disease was 1.09%. Age of most patients were between 26-30 years, 44.68%. Most of patients were multiparous57.44%. According to NYHA classification, 63.82% had class 3 & 4 cardiac disease. Rheumaticheart disease was present in 91.48%. Thirty patients were delivered by caesarean section. Therewere 3 IUD and 2 perinatal deaths. Maternal mortality was 2.12%. Preterm delivery occurredin 20 patients. Conclusion: Cardiac disease is important cause of maternal and perinatalmorbidity and mortality. It’s important to counsel all women of reproductive age with knowncardiac disease, about increased fetal and maternal risk during pregnancy. Cesarean sectionmay be considered in patients with moderate or severe MS with class 3-4 symptoms.

Style APA, Harvard, Vancouver, ISO itp.

36

Mohan, Naina, i Catherine Nelson-Piercy. "Neurological disease in pregnancy". Obstetrics, Gynaecology & Reproductive Medicine 32, nr 1 (styczeń 2022): 14–19. http://dx.doi.org/10.1016/j.ogrm.2021.11.003.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

37

Babadjanova Guljakhon Sattarovna i Uzakova Manzura Kamilovna. "Heart disease in pregnancy". GSC Biological and Pharmaceutical Sciences 15, nr 3 (30.06.2021): 116–23. http://dx.doi.org/10.30574/gscbps.2021.15.3.0151.

Pełny tekst źródła

Streszczenie:

Heart disease are common condition in pregnant women. Even, some of the cases diagnose just during the pregnancy. In this article, we summarize common cardiac disorders, which might encounter during the pregnancy and after birth. Furthermore, we discuss some etiological factors, pathophysiology, clinical manifestation, treatment and outcomes of the cardiac disease in pregnancy.

Style APA, Harvard, Vancouver, ISO itp.

38

Heffner, John E., i Steven A. Sahn. "PLEURAL DISEASE IN PREGNANCY". Clinics in Chest Medicine 13, nr 4 (grudzień 1992): 667–78. http://dx.doi.org/10.1016/s0272-5231(21)01134-5.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

39

Valassi, Elena. "Pituitary disease and pregnancy". Endocrinología, Diabetes y Nutrición (English ed.) 68, nr 3 (marzec 2021): 184–95. http://dx.doi.org/10.1016/j.endien.2020.07.002.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

40

Dadkhah, Narjeskhaton, Bahareh Motaghi i Leili Abedi Gheshlaghi. "Pregnancy and coronavirus disease". Journal of Multidisciplinary Care 10, nr 2 (30.06.2021): 54–55. http://dx.doi.org/10.34172/jmdc.2021.10.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

41

Gungor, A. N. C., G. Kalkan, S. Oguz, B. Sen, P. Ozoguz, Z. Takci, H. Sacar, F. B. Dogan i D. Cicek. "Behcet disease and pregnancy". Clinical and Experimental Obstetrics & Gynecology 41, nr 6 (10.12.2014): 617–19. http://dx.doi.org/10.12891/ceog16762014.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

42

Asselin-Miller, Natasha, i Charlotte Patient. "Renal disease in pregnancy". Obstetrics, Gynaecology & Reproductive Medicine 32, nr 3 (marzec 2022): 27–31. http://dx.doi.org/10.1016/j.ogrm.2022.01.001.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

43

Nakash, A., A. Arafa i T. Datta. "Heart disease in pregnancy". Journal of Obstetrics and Gynaecology 29, nr 8 (styczeń 2009): 767–68. http://dx.doi.org/10.3109/01443610903182839.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

44

Yadav, Vikas, i Ankita Priya. "Cardiovascular Disease in Pregnancy". Scholars International Journal of Obstetrics and Gynecology 02, nr 11 (30.11.2019): 288–92. http://dx.doi.org/10.36348/sijog.2019.v02i11.007.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

45

Parent, Emily, Joseph R. Wax, Wendy Smith, Hagen Blaszyk, Michael G. Pinette, Angelina Cartin i Jacquelyn Blackstone. "Fabry disease complicating pregnancy". Journal of Maternal-Fetal & Neonatal Medicine 23, nr 10 (luty 2010): 1253–56. http://dx.doi.org/10.3109/14767050903580391.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

46

Kim, Jong In. "Thyroid disease in pregnancy". Journal of the Korean Medical Association 59, nr 1 (2016): 31. http://dx.doi.org/10.5124/jkma.2016.59.1.31.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

47

vander Weiden, R. M. F. "Hydatid disease in pregnancy". Journal of Obstetrics and Gynaecology 10, nr 2 (styczeń 1989): 128–29. http://dx.doi.org/10.3109/01443618909151130.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

48

Rychik, Jack. "Pregnancy and cardiovascular disease". Expert Review of Cardiovascular Therapy 8, nr 6 (czerwiec 2010): 759–61. http://dx.doi.org/10.1586/erc.10.40.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

49

Mikkelse, A. L., i C. Palle. "Lyme disease during pregnancy". Acta Obstetricia et Gynecologica Scandinavica 66, nr 5 (styczeń 1987): 477–78. http://dx.doi.org/10.3109/00016348709022058.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

50

Albert, Eva, Knut Dalaker, Rolf Jorde i Lillian Nordbø Berge. "Addison's Disease and Pregnancy". Acta Obstetricia et Gynecologica Scandinavica 68, nr 2 (styczeń 1989): 185–87. http://dx.doi.org/10.3109/00016348909009909.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!